Dong-A ST Confirms Potential to Develop 'Icotrokinra' as a Topical Treatment
Nonclinical Results Presented at AAPS 2026
Dong-A ST confirmed in a nonclinical study the potential to develop icotrokinra, an ingredient in an oral psoriasis treatment, as a topical formulation applied to the skin.
On October 27, Dong-A ST said it had presented the findings in a poster at AAPS PharmSci 360 2026, a conference of the American Association of Pharmaceutical Scientists (AAPS) being held in New Orleans, U.S., from October 25 to 28 local time. The researchers assessed skin penetration and retention outside the human body and developed a topical formulation that can deliver icotrokinra through the skin. In an animal model with induced skin inflammation, the formulation alleviated inflammation and suppressed the gene expression of IL-17A, IL-17F and IL-22, inflammatory cytokines associated with psoriasis.
Icotrokinra is an oral peptide that selectively binds to the interleukin-23 (IL-23) receptor, which transmits inflammatory signals, and blocks those signals. An oral treatment based on the ingredient received approval from the U.S. Food and Drug Administration (FDA) in March 2026. The presentation was delivered by Kim Haeseon, a senior researcher on Dong-A ST's drug delivery system (DDS) team.
The market for treatments for inflammatory skin conditions such as psoriasis is growing as formulations diversify to include oral and topical medications. Global investment bank Bank of America forecasts peak annual sales of $4.5 billion for an oral treatment based on icotrokinra. In the topical market, Incyte's JAK inhibitor Opzelura generated about $678 million in sales last year, while Organon's Vtama generated about $128 million.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Dong-A ST official said, "For more than a decade, we have built up our drug delivery technology and R&D capabilities through research into a range of formulations, including patches, transdermal drug delivery and topical products. Building on our accumulated technology and experience, we will continue to pursue the development of new formulations for a variety of drugs."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.